Related Experiment Video
Updated: May 9, 2026
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Drug-Induced Liver Injury Secondary to Radionuclide Therapy With Lutetium-177 Vipivotide Tetraxetan in a Patient With
Brian T Lee1, Ravi J Kankotia2, David Braxton3
1Liver Program, Hoag Digestive Health Institute, Hoag Memorial Hospital Presbyterian, Newport Beach, CA.
Abstract:
Lutetium-177 vipivotide tetraxetan (LuPSMA) is a small molecule inhibitor with high affinity to prostate-specific membrane antigen and is currently used in the treatment of metastatic castrate-resistant prostate cancer. Hepatotoxicity has seldom been reported. This is a case of drug-induced liver injury presenting in a patient who received 5 cycles of LuPSMA for metastatic castrate-resistant prostate cancer. In this report, we provide a probable case of drug-induced liver injury with imaging and histologic findings of cholestatic liver injury and stricturing cholangiopathy related to LuPSMA. This is the first report of LuPSMA as a probable cause of hepatotoxicity.
Insights
Lutetium-177 vipivotide tetraxetan (LuPSMA) may cause drug-induced liver injury in patients with metastatic castrate-resistant prostate cancer. This case report details liver injury, including cholestatic findings and stricturing cholangiopathy, linked to LuPSMA treatment.
Area of Science:
- Oncology
- Hepatology
- Radiopharmaceuticals
Background:
- Lutetium-177 vipivotide tetraxetan (LuPSMA) is a targeted radiopharmaceutical therapy for metastatic castrate-resistant prostate cancer (mCRPC).
- While effective, potential adverse effects require ongoing investigation.
- Hepatotoxicity from LuPSMA is rarely documented.
